Pfizer scores again with the FDA is gaining the agency's agreement to provide priority review for it drug crizotinib for the treatment of specific non-small cell lung cancers (NSCLC). The company said it had also filed a marketign application with regulatory authorities in Japan.
Crizotinib is viewed as one of Pfizer's next best chances at a blockbuster to help replace lost revenues that will come from its drugs like Lipitor coming off patent.
"Given the clinical trial results seen to date, we believe that crizotinib, if approved, may change the treatment paradigm for patients with ALK-positive advanced NSCLC," said Garry Nicholson, president and general manager, Pfizer Oncology Business Unit. See Fierce Biotech.
Posted by Bruce Lehr May 17th 2011.